Edgewise Therapeutics-2026-JPM.pdf

1、1 1Edgewise TherapeuticsEdgewise TherapeuticsThe 44thAnnual J.P.Morgan Healthcare ConferenceJanuary 13,2026Kevin Koch,CEO2Forward Looking StatementThis presentation contains contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of th

2、e Securities Exchange Act of 1934.Statements in this presentation that are not purely historical are forward-looking statements.Such forward-looking statements include,among other things,statements regarding the potential of,and expectations regarding,Edgewises product candidates and programs,includ

3、ing sevasemten,EDG-7500,EDG-15400 and its cardiovascular programs;statements regarding the ability of the Company to establish sevasemten as the first approved therapy,becoming a commercial company and executing the first-in-disease launch in Becker;statements regarding bringing transformative medic

4、ines to patients;statements regarding the market opportunity for sevasemten in Becker an EDG-7500;statements regarding Edgewises expectations relating to its clinical trials,including timing of the completion of the GRAND CANYON trial,finalizing design for the Companys Phase 3 program in obstructive

5、 and nonobstructive HCM,timing of reporting data(including top-line data of sevasemten,Phase 2 results for EDG-7500 in HCM,the presentation of data from the GRAND CANYON trial and the presentation of data from the Phase 1 trial of EDG-15400)and timing of initiation of clinical trials(including Phase

6、 3 trials in individuals with HCM and Duchenne and Phase 2 trial of EDG-15400);statements regarding Edgewises ability to advance its pipeline;statements regarding the companys ability to achieve milestones;statement regarding the companys cash runway;risks associated with Edgewise gaining further in